BioNTech

A Turkish study of 64 patients found measurable corneal changes 75 days after receiving two doses of the Pfizer-BioNTech COVID-19 vaccine, including 2% increased thickness and 8% reduced endothelial cell density.

Ryan Richardson will step down as Chief Strategy Officer from BioNTech's Management Board on September 30, 2025, after serving since January 2020.

Regeneron Pharmaceuticals and BioNTech SE are conducting a Phase 2 clinical trial evaluating the combination of investigational cancer vaccine BNT116 with cemiplimab versus cemiplimab monotherapy in advanced non-small cell lung cancer patients with PD-L1 expression ≥50%.

Sartorius Stedim Biotech and Sensible Biotechnologies have signed a Memorandum of Understanding to advance the industrialization of Sensible's first-in-class cell-based mRNA manufacturing platform.

Everest Medicines unveiled major breakthroughs in its proprietary AI-powered mRNA platform during its 2025 R&D Day, showcasing a fully integrated system spanning antigen design to manufacturing.

NCT/UCC Dresden becomes the only site in Saxony to offer patients access to BioNTech and Genentech's personalized mRNA vaccine Autogene Cevumeran for pancreatic cancer treatment.

BioNTech will lay off 63 employees and wind down cell therapy manufacturing at its Gaithersburg, Maryland facility by the end of 2025 following disappointing Phase 1 trial results.

BioNTech announced a $1.25 billion all-stock acquisition of CureVac through a public exchange offer, offering $5.46 per CureVac share representing a 55% premium to strengthen its mRNA-based cancer immunotherapy capabilities.

Health Secretary Robert F. Kennedy Jr. has replaced all 17 members of the CDC's Advisory Committee on Immunization Practices with eight new appointees, significantly downsizing the committee.

Bristol Myers Squibb will pay BioNTech $1.5 billion upfront plus $2 billion in anniversary payments through 2028 for a 50% partnership in BNT327, a bispecific antibody targeting both PD-L1 and VEGF proteins.